Adverse Effects and Safety

The prospective design with centralised imaging review is identified as a methodological strength that reduces inter-observer variability in efficacy evaluations. GLP-1 medications impair oral contraceptive effectiveness through delayed gastric emptying. GLP-1 medications can alter the absorption of all orally administered drugs due to delayed gastric emptying. Pancreatitis risk with GLP-1 receptor agonists is compounded when combined with DPP-4 inhibitors. IBI305 requires temporary or permanent discontinuation before elective surgery, for severe infusion reactions, for moderate-to-severe proteinuria, or for poorly controlled severe hypertension. All GLP-1 receptor agonists carry a black box warning and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. GI side effects including nausea, vomiting, diarrhea, constipation, and abdominal pain are the most frequently reported adverse effects, most commonly occurring at initiation or dose escalation. Immunotherapy combination regimens carry a risk of severe immune-related adverse events requiring close monitoring and prompt management throughout treatment. All GLP-1 agents should be…